Analytical Data
-
基因名
TGFBR3/TGF-beta RIII
- Application
-
别名
TGFBR3; TGF-bRIII; TGFR-3; Transforming growth factor beta receptor III; Betaglycan
-
种属
Human
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q03167
-
表达区间
G21-V787
-
蛋白长度
Partial
-
分子量
100 kDa and 130-170 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Transforming growth factor-beta receptor 3 (TGFBR3), also known as the TGF-beta RIII, plays a crucial role in the TGF-beta signaling pathway, which is pivotal for various cellular processes, including proliferation, differentiation, and apoptosis. TGFBR3 acts as a co-receptor that enhances the binding of TGF-beta ligands to their primary receptors, TGFBR1 and TGFBR2, thereby modulating the signal transduction pathways that are essential for maintaining cellular homeostasis. Dysregulation of TGFBR3 has been implicated in numerous pathological conditions, including fibrosis, cancer, and autoimmune diseases, highlighting its potential as a therapeutic target. Recent studies have focused on the generation of recombinant TGFBR3 proteins to investigate their functional roles in these diseases, as well as to explore their utility in therapeutic applications. The recombinant protein can be used to better understand the mechanisms of TGF-beta signaling, and it provides a valuable tool for drug screening and development. Additionally, the ability to produce large quantities of purified TGFBR3 paves the way for potential clinical applications, including the design of targeted therapies aimed at modulating TGF-beta activity in various disease contexts. Research into TGFBR3 continues to evolve, emphasizing its importance as a critical mediator in TGF-beta signaling and its relevance in the development of innovative treatments.
